211 related articles for article (PubMed ID: 26582645)
1. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
[TBL] [Abstract][Full Text] [Related]
3. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S
J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
7. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
[TBL] [Abstract][Full Text] [Related]
8. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Wang JH; Chen WL; Li JM; Wu SF; Chen TL; Zhu YM; Zhang WN; Li Y; Qiu YP; Zhao AH; Mi JQ; Jin J; Wang YG; Ma QL; Huang H; Wu DP; Wang QR; Li Y; Yan XJ; Yan JS; Li JY; Wang S; Huang XJ; Wang BS; Jia W; Shen Y; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17017-22. PubMed ID: 24082129
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
12. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
13. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
15. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
16. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
[TBL] [Abstract][Full Text] [Related]
19. The role of IDH mutations in acute myeloid leukemia.
Montalban-Bravo G; DiNardo CD
Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
